Each patient received a detailed ophthalmologic examination including measurement of BCVA according to the standardized ETDRS refraction protocol using a retroilluminated Lighthouse for the Blind distance visual acuity test chart (using modified ETDRS charts 1, 2, and

R; Precision Vision, IL), as well as applanation tonometry, undilated and dilated slit-lamp biomicroscopic examination, indirect fundus examination, and fluorescein angiography using high-resolution angiography (HRA; Heidelberg Engineering, Heidelberg, Germany). Fourier-domain OCT evaluation (Spectralis Eyetracker Tomographer, HRA-OCT; Heidelberg Engineering) was performed in all patients, and retinal thickness measurements were acquired using a standard

20 × 15-degree raster scan protocol consisting DAPT in vitro of 19 horizontal sections (each computed out of 25 frames) with find more a distance of 240 μm between each horizontal scan, covering a square of 20 × 15 degrees on the retina and centered on the foveal region. Follow-up mode was used to reduce test-retest variability. In order to optimize the accuracy of OCT data, automatic delineation of the inner and outer boundaries of the neurosensory retina generated by OCT built-in software was verified for each of the scans. Central subfield thickness values were calculated automatically as the average thickness of a central macular region 1000 μm in diameter centered on the patient’s foveola by built-in Heidelberg software using retinal map analysis. If both eyes were eligible for treatment and the patient

agreed to treat both eyes with anti-VEGF therapy, Sclareol 1 eye received the randomized treatment according to a computer-generated sequence and the contralateral eye received the other anti-VEGF agent on the next day; thus, if an eye was randomized to the ranibizumab group, the contralateral eye was allocated to the bevacizumab group. All injections were performed using topical proparacaine drops under sterile conditions (eyelid speculum and povidone-iodine). Before the injection was performed, the eyelids were scrubbed with 10% povidone-iodine, and 5% povidone-iodine drops were applied to the conjunctiva. The time between application of 5% povidone-iodine solution to the conjunctiva and administration of the intravitreal injection was 2 minutes. Povidone-iodine was applied to the conjunctiva directly over the intended injection site.17, 18, 19 and 20 Care was taken in all cases to insure that the needle did not touch the lids or lashes. Bevacizumab (1.5 mg/0.06 cc; F.